In his remarks, Mazen Darwazah, Executive Vice Chairman and President of MENA at Hikma, said:
We are proud to expand our collaboration with Celltrion. By working together more closely, we can bring more high-quality, cost-effective biologic therapies to patients across MENA.
This collaboration targets therapeutic areas including oncology, immunology and chronic disease management, with plans to introduce biosimilars for monoclonal antibodies and other advanced biologic classes. Each product will undergo local regulatory approvals in individual markets, tailored to the healthcare systems across the region.
Strategic context and outlook
Hikma’s role as a regional pharmaceutical leader positions it to manage market access, distribution, regulatory affairs and local commercial functions across 17 MENA markets. By partnering with Celltrion, whose technical capabilities in biologics are well established, the alliance aims to overcome infrastructure and investment barriers in the region’s biosimilar adoption. Hikma has already launched multiple Celltrion biosimilars—including Truxima (rituximab), Remsima (infliximab) and Herzuma (trastuzumab) — and is progressing further launches.
Going forward, the partners intend to coordinate on medical education, pharmacovigilance, and sustainability initiatives to support safe and responsible biosimilar adoption. This expansion signals an ambition to narrow treatment gaps, reduce healthcare costs, and increase access to biologic therapies in markets that have historically faced limited supply or affordability challenges.
